P19-09. Site-specific incorporation of an unnatural amino acid into the HIV-1 Env spike

por Arnett, SO, Burton, DR
Publicado 2009

P04-05. Requirements for antibody domain exchange explored through mutation of the germline 2G12 antibody

por Huber, M, Le, KM, Doores, KJ, Burton, DR
Publicado 2009

P04-38. Crystal structure of gp120 in complex with the CD4-binding-site antibody b13 suggests precise targeting is needed for neutralization

por Zhou, T, Yang, Z, Xu, L, Hessell, AJ, Burton, DR, Nabel, GJ, Kwong, PD
Publicado 2009

P12-06. A 'non-self' mimic of the natural epitope of anti-HIV antibody 2G12 shows enhanced antigenicity

por Doores, KJ, Fulton, Z, Scanlan, CN, Wormald, MR, Dwek, RA, Wilson, IA, Burton, DR, Davis, BG
Publicado 2009

MAb PGT121 protects against mucosal SHIV challenge in macaques at concentrations corresponding to its highly potent in vitro neutralization capacity

por Moldt, B, Rakasz, EG, Schultz, N, Chan-Hui, P, Swiderek, K, Watkins, DI, Burton, DR, Poignard, P
Publicado 2012

Biodistribution of neutralizing monoclonal antibodies IgG1 b12 and LALA in mucosal and lymphatic tissues of rhesus macaques

por Hessell, AJ, Epson, E, Moldt, B, Rakasz, E, Pandey, S, Sutton, WF, Brower, Z, Hirsch, VM, Burton, DR, Haigwood, NL
Publicado 2012

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable

por Xu, H, Scherer, E, Song, L, Kim, M, Holmes, MA, Sellhorn, G, Kraft, Z, Reinherz, EL, Burton, DR, Stamatatos, L, Strong, RK
Publicado 2009

Structural comparison of somatically related PG9 and PG16 in complex with their epitope reveals differences in glycan recognition

por Pancera, M, McLellan, JS, Shahzad-ul-Hussan, S, Doria-Rose, N, Zhang, B, Yang, Y, Burton, DR, Koff, WC, Bewley, CA, Kwong, PD
Publicado 2012

Rational immunogen design to target specific germline B cell receptors

por Jardine, J, Kalyuzhniy, O, Ota, T, McGuire, A, Menis, S, Julien, J, Falkowska, E, MacPherson, S, Jones, M, Burton, DR, Wilson, IA, Stamatatos, L, Nemazee, D, Schief, WR
Publicado 2012

A short segment in the HIV-1 gp120 V1/V2 region is a major determinant of neutralization resistance to PG9-like antibodies

por Doria-Rose, NA, Georgiev, I, Staupe, RP, O'Dell, S, Chuang, G, Gorman, J, McLellan, JS, Pancera, M, Bonsignori, M, Haynes, BF, Burton, DR, Koff, WC, Kwong, PD, Mascola, JR
Publicado 2012

P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors

por Binley, J, Wrin, T, Pantophlet, R, Phung, P, Crooks, ET, Lapedes, A, Taylor, N, Cavacini, L, Steigler, G, Kunert, R, Katinger, H, Petropoulos, C, Richman, D, Morris, L, Sutthent, R, Burton, DR
Publicado 2009

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies

por Julien, J, Kong, L, Pejchal, R, Khayat, R, Lee, J, Stanfield, RS, Walker, LM, Doores, KJ, Folkowska, E, Poignard, P, Depetris, R, Sanders, RW, Koff, WC, Moore, JP, Ward, AB, Burton, DR, Wilson, IA
Publicado 2012

Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology

por Nemazee, D, Doyle-Cooper, C, Ota, T, Cooper, AB, Huber, M, Falkowska, E, Doores, K, Hangartner, L, Le, K, Sok, D, Jardine, J, Lifson, J, Wu, X, Mascola, JR, Poignard, P, Binley, JM, Chakrabarti, BK, Schief, WR, Wyatt, RT, Burton, DR
Publicado 2012